Trial Profile
A Phase 2b/3, Double-blind, Randomized, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Praconase (Primary)
- Indications Spinal cord injuries
- Focus Therapeutic Use
- Acronyms SPRING
- Sponsors Vertex Pharmaceuticals
- 20 Dec 2018 Status changed from active, no longer recruiting to discontinued.
- 20 Nov 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 20 Nov 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.